BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)


Royce M., Villanueva C., Ozguroglu M., Bachelot T., Azevedo S., Melo Cruz F., ...Daha Fazla

41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27 identifier

  • Cilt numarası: 27
  • Doi Numarası: 10.1093/annonc/mdw365.1
  • Basıldığı Şehir: Copenhagen
  • Basıldığı Ülke: Danimarka